-
Challenge Kelun's leading position!
Time of Update: 2021-03-23
According to data from Meinenet, the sales of terminal bromhexine hydrochloride injections in China's public medical institutions exceeded 2 billion yuan in 2019.
According to data from Meinenet, the sales of terminal bromhexine hydrochloride injections in China's public medical institutions exceeded 2 billion yuan in 2019.
-
Buchang Pharmaceutical Xuanfeibaidu Granules Approved for Listing
Time of Update: 2021-03-23
On March 4, Buchang Pharmaceutical issued an announcement stating that it had recently received the "Drug Registration Certificate" on Xuanfeibaidu Granules approved and issued by the State Food and Drug Administration.
-
GSK Central Nervous Drugs Approved in China for New Indications for Treatment of Bipolar Disorder
Time of Update: 2021-03-23
On March 3, GlaxoSmithKline (GSK) issued a press release stating that the new indications of Rapidone (generic name: Lamotrigine Dispersible Tablets) have been approved by the National Medical Products Administration (NMPA).
-
The net profit of 9 Chinese medicine companies exceeded 100%!
Time of Update: 2021-03-23
Zuoli Pharmaceuticals stated in the performance forecast that taking advantage of the core products Wuling Capsules, Bailing Tablets, and Lingze Tablets to enter the National Essential Drug List, increasing market investment and the development and coverage of terminal medical institutions are the main factors for performance growth.
-
Global pharmaceutical companies ranked TOP10! Johnson and Johnson, Roche, Novarter...
Time of Update: 2021-03-23
According to the revenue statistics of the pharmaceutical business, the top 10 global pharmaceutical companies are ranked in order: Roche, Novartis, AbbVie, Johnson & Johnson, Merck, Bristol-Myers Squibb, Pfizer, Sanofi, GlaxoSmithKline, and Takeda.
-
Background interpretation of the current round of revision of the Regulations on the Supervision and Administration of Medical Devices
Time of Update: 2021-03-23
34 ，。200014《》（《》），《》、、、。，，20142017、、。 20201221，《（）》（《》）。《》、、。 《》，： ：，、 20，800025000，，。 2014， 20%，。15%，。 2020，，，。，。，。。 ：， 2017“”《》，、、，。 1. 。201712，《（）》，，，。20198，《》，、、、、、、。，，，。 《》，、、、、；、、。 2
-
The local government was investigated for monopolizing the purchasing power of consumables and pharmaceutical equipment distribution!
Time of Update: 2021-03-23
Strengthen anti-monopoly law enforcement Focus on the fields of medicine, bidding and government procurement When it comes to preventing the abuse of administrative power to restrict competition, I have to talk about the recent comprehensive clean-up of regulations and practices that hinder the unified market and fair competition in the Guangdong-Hong Kong-Macao Greater Bay Area.
-
Osaikon's subsidiary Pipexili Capsules application for marketing authorization was accepted
Time of Update: 2021-03-23
CDK4/6 inhibitors are effective drugs for reversing endocrine therapy resistance, and their combined use with endocrine therapy has now been included in the treatment guidelines for advanced HR-positive breast malignancies.
-
First Weida Bio-NASH new drug was approved to carry out clinical research
Time of Update: 2021-03-23
Previously, XW003 has obtained two clinical trial approvals in 2020 for two indications of type 2 diabetes and weight management for obese/overweight patients.
In 2021, Winstar will carry out phase II clinical trials for a number of metabolic diseases (diabetes, obesity, NASH, etc.
-
Drug Administration: Catalog of Generic Drug Ginseng Preparations (39th Batch)
Time of Update: 2021-03-23
35 34，，（）。 。 ：（） 76%; height: 30px"> 42%; height: 30px"> 06%; height: 30px"> / 96%; height: 30px"> 3%; height: 30px"> 4%; height: 30px"> 1 06%; height: 30px"> 2 76%; height: 30px"
-
Orphan drug research and development progress 5 pictures in seconds
Time of Update: 2021-03-23
Because of the small number of patients with rare diseases, low market demand, and high research and development costs, companies are not very enthusiastic about developing orphan drugs, but because all countries have introduced them A series of encouraging policies have been adopted.
-
The State Drug Administration issued a document: 226 drugs written off
Time of Update: 2021-03-23
Low drug prices make pharmaceutical companies withdraw from the market The drugs with the highest number of cancellations this time are acetaminophen tablets and captopril tablets, and seven approvals have been cancelled respectively.
-
Rare disease day focuses on multiple sclerosis
Time of Update: 2021-03-23
Among them, multiple sclerosis (MS) is a rare disease, and many drugs have been approved in recent years.
In August 2020, ofatumumab subcutaneous injection was approved by the FDA for the treatment of adult relapsing multiple sclerosis, including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease.
-
AZ new crown vaccine real world data released, one shot reduces the risk of illness and hospitalization in the elderly
Time of Update: 2021-03-23
The current accumulated data shows that the effectiveness of this vaccine in preventing symptomatic COVID-19 reaches 60-73% in elderly people over 70 years old, 4 weeks after a single vaccination.
-
The new version of the medical insurance catalog is implemented, and a batch of new policies for pharmacies will be implemented soon!
Time of Update: 2021-03-23
In addition to the official implementation of the 2020 National Medical Insurance Catalogue, a number of new pharmaceutical policies have been or will be implemented starting from 2021, many of which are closely related to the pharmacy industry or the lives of the people.
-
February 2021 | TOP5 failed clinical studies
Time of Update: 2021-03-23
Phase III study of BAT8001 in the treatment of breast cancerOn the evening of February 8, Biotech issued an announcement stating that the phase III clinical efficacy index of the HER2 ADC drug BAT8001 did not reach the preset level of progression-free survival (PFS) compared with the control group (lapatinib combined with capecitabine) The goal of superiority.
-
GlaxoSmithKline/Vir suspends monoclonal antibody VIR-7831 and enrolls in key phase 3 clinical patients
Time of Update: 2021-03-23
Vir Biotechnology and GSK provide update on NIH-sponsored ACTIV-3 trial evaluating VIR-7831 in hospitalised adults with COVID-19
-
Implementation of the new version of the medical insurance catalogue, 119 national talks officially reduced the price of drugs
Time of Update: 2021-03-23
Tilelizumab: For example, BeiGene's star product tislelizumab (BaiZian), the indication for entering the medical insurance this time is the treatment of relapsed or refractory classic Hodgkin's lymphoma after at least second-line chemotherapy; PD- The failure of platinum-containing chemotherapy with high L1 expression includes the treatment of locally advanced or metastatic urothelial carcinoma that has progressed within 12 months of neoadjuvant or adjuvant chemotherapy.
-
226 drug approvals were written off, and pharmaceutical companies cleaned up nearly two-thirds of the approvals at once!
Time of Update: 2021-03-23
Taking the more noticeable Jiangsu Huanghe Pharmaceutical Industry this time around, all of its cancellations are hot products such as azithromycin dispersible tablets, aspirin enteric-coated tablets, and ibuprofen capsules, which are in huge clinical use.
-
Tianyao's Tameasone Sodium Phosphate API passed the technical review of the NMPA Drug Evaluation Center
Time of Update: 2021-03-23
announced that the company’s betamethasone sodium phosphate API passed the technical review by the Drug Evaluation Center of the National Medical Products Administration, and was displayed on the CDE API, pharmaceutical excipients and pharmaceutical packaging materials registration information publicity platform The registration status indicator is changed to "A".
